Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis.
CA125
Co-expression
Endometrial carcinoma
Gynecologic carcinoma
Mesothelin
Prognosis
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
08 Apr 2021
08 Apr 2021
Historique:
received:
20
02
2021
accepted:
30
03
2021
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
18
11
2021
Statut:
epublish
Résumé
This study aimed to investigate the association between clinicopathologic factors, mesothelin, and cancer antigen (CA) 125 in endometrial carcinoma. Between 1989 and 2017, patients with endometrial carcinoma who underwent total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either or both immunochemical expression of mesothelin and CA125 and clinicopathological features were retrospectively examined. Among 485 patients, 171 were positive for mesothelin, 368 were positive for CA125, and 167 were positive for mesothelin and CA125. The expression of mesothelin and CA125 was positively correlated (p < 0.01). More patients with mesothelin expression showed myometrial invasion of more than 50% (p = 0.028) and positive lymphovascular invasion (p = 0.027). Similarly, more patients with co-expression of mesothelin and CA125 had myometrial invasion of more than 50% (p = 0.016) and positive lymphovascular invasion (p = 0.02). Patients with mesothelin expression and co-expression of mesothelin and CA125 demonstrated worse progression-free survival (PFS) and overall survival (OS). In the multivariate analysis, mesothelin expression and co-expression were poor prognostic factors for PFS (mesothelin expression: hazard ratio [HR] = 2.14, p < 0.01; co-expression: HR = 2.19, p < 0.01) and OS (mesothelin expression: HR = 2.18, p < 0.01; co-expression: HR = 2.22, p < 0.01). Mesothelin expression and co-expression might be associated with tumor aggressiveness and poor prognosis in patients with endometrial carcinoma. Persons with mesothelin-expressing endometrial cancers present a particularly high medical unmet need.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to investigate the association between clinicopathologic factors, mesothelin, and cancer antigen (CA) 125 in endometrial carcinoma.
METHODS
METHODS
Between 1989 and 2017, patients with endometrial carcinoma who underwent total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either or both immunochemical expression of mesothelin and CA125 and clinicopathological features were retrospectively examined.
RESULTS
RESULTS
Among 485 patients, 171 were positive for mesothelin, 368 were positive for CA125, and 167 were positive for mesothelin and CA125. The expression of mesothelin and CA125 was positively correlated (p < 0.01). More patients with mesothelin expression showed myometrial invasion of more than 50% (p = 0.028) and positive lymphovascular invasion (p = 0.027). Similarly, more patients with co-expression of mesothelin and CA125 had myometrial invasion of more than 50% (p = 0.016) and positive lymphovascular invasion (p = 0.02). Patients with mesothelin expression and co-expression of mesothelin and CA125 demonstrated worse progression-free survival (PFS) and overall survival (OS). In the multivariate analysis, mesothelin expression and co-expression were poor prognostic factors for PFS (mesothelin expression: hazard ratio [HR] = 2.14, p < 0.01; co-expression: HR = 2.19, p < 0.01) and OS (mesothelin expression: HR = 2.18, p < 0.01; co-expression: HR = 2.22, p < 0.01).
CONCLUSIONS
CONCLUSIONS
Mesothelin expression and co-expression might be associated with tumor aggressiveness and poor prognosis in patients with endometrial carcinoma. Persons with mesothelin-expressing endometrial cancers present a particularly high medical unmet need.
Identifiants
pubmed: 33832498
doi: 10.1186/s13000-021-01093-4
pii: 10.1186/s13000-021-01093-4
pmc: PMC8034188
doi:
Substances chimiques
CA-125 Antigen
0
GPI-Linked Proteins
0
MUC16 protein, human
0
Membrane Proteins
0
Mesothelin
J27WDC343N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
28Références
Mol Cancer. 2006 Oct 26;5(1):50
pubmed: 17067392
CA Cancer J Clin. 2019 Jul;69(4):258-279
pubmed: 31074865
Mol Cancer Ther. 2016 Mar;15(3):439-47
pubmed: 26823490
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S93-S113
pubmed: 30550486
J BUON. 2019 Jul-Aug;24(4):1549-1554
pubmed: 31646807
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31
pubmed: 16467095
Mol Cancer. 2014 May 29;13:129
pubmed: 24886523
Virchows Arch. 2019 Mar;474(3):297-307
pubmed: 30603773
Int J Cancer. 1992 Feb 1;50(3):373-81
pubmed: 1735605
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591
Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5
pubmed: 12144685
Int J Gynecol Pathol. 2017 Mar;36(2):128-139
pubmed: 27167671
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
Oncol Lett. 2015 Apr;9(4):1583-1589
pubmed: 25789005
Arch Gynecol Obstet. 2020 Nov;302(5):1255-1262
pubmed: 32815024
J Clin Oncol. 2016 Dec;34(34):4171-4179
pubmed: 27863199
Breast Cancer Res Treat. 2014 Oct;147(3):675-84
pubmed: 25193277
Gynecol Oncol. 2015 Jun;137(3):581-8
pubmed: 25805398
Obstet Gynecol. 2012 Aug;120(2 Pt 1):383-97
pubmed: 22825101
J Biol Chem. 2004 Mar 5;279(10):9190-8
pubmed: 14676194
Gynecol Oncol. 2007 Jun;105(3):563-70
pubmed: 17400285
J Pathol. 2017 Oct;243(2):230-241
pubmed: 28718916
Br J Cancer. 2012 Jun 26;107(1):137-42
pubmed: 22644300
Mol Cancer. 2011 Aug 31;10:106
pubmed: 21880146
J Gynecol Oncol. 2019 Sep;30(5):e84
pubmed: 31328462
Pancreas. 2011 Nov;40(8):1276-82
pubmed: 21775916
Eur J Gynaecol Oncol. 2008;29(5):489-92
pubmed: 19051819
Mol Cancer. 2017 Mar 14;16(1):63
pubmed: 28288645
Oncol Lett. 2020 Mar;19(3):1741-1750
pubmed: 32194667
J Surg Oncol. 2012 Feb;105(2):195-9
pubmed: 21780126
Virchows Arch. 2017 Jan;470(1):63-68
pubmed: 27787595
Am J Clin Pathol. 2019 Oct 7;152(5):616-624
pubmed: 31318970
Cancer Treat Res Commun. 2020;25:100260
pubmed: 33310366
Biomark Res. 2019 Aug 23;7:18
pubmed: 31463062
Pathol Oncol Res. 2020 Oct;26(4):2299-2306
pubmed: 32468249
Eur J Surg Oncol. 2019 Feb;45(2):218-224
pubmed: 30348604